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Background Zotarolimus eluting stent(ZES) is a new drug eluting stent which delivers zotarolimus through a biocompatible phosphorylcholine 
polymer. But, its efficacy against sirolimus eluting (SES) and paclitaxel eluting stents (PES) is yet to be proven. We aimed to summarize the current 
evidence from randomized trials comparing ZES to SES and PES.
Methods We searched Medline, Embase and CENTRAL database for randomized studies comparing ZES to SES and PES for coronary intervention. 
Relevant clinical and angiographic outcomes were extracted and combined using random and fixed effect model for heterogeneous and 
homogeneous outcomes respectively.
Results Six randomized trials met the inclusion criterion, including 3,448 patients in ZES group, 2,227 patients in SES group and 1,966 
patients in PES group. ZES use was associated with higher odds of major adverse cardiac events, ischemia driven target vessel and target lesion 
revascularization compared to SES. ZES also had higher in-stent restenosis (OR = 5.63 95% CI 3.94-8.04), and late lumen loss “in-stent” (mean 
difference (MD) = 0.42 mm 95% CI 0.36-0.48) and “in-segment” (MD = 0.19 mm 95% CI 0.16-0.22) than SES. ZES was also associated with higher 
in-stent late lumen loss (MD = 0.18 mm 95% CI 0.07-0.29) than PES. There was no difference in mortality; re-infarction or stent thromboses with 
ZES use compared to SES and PES.
Conclusion ZES is not superior to PES, and inferior to SES in terms angiographic outcomes, and ischemia driven revascularization. 
Outcomes - ZES vs SES and PES,
Outcome
ZES vs SES 
Odds ratio ( 95% CI)
P value
ZES vs PES 
Odds ratio (95% CI)
P value
MACE 1.53 (1.03-2.28) 0.04 0.85 (0.69-1.05) 0.14
Mortality 1.20 (0.83-1.73) 0.33 1.11 (0.59-2.06) 0.75
Re-infarction 0.98(0.70-1.36) 0.9 0.76(0.55-1.04) 0.09
Ischemia driven TVR 2.24 (1.50-3.34) <0.0001 0.85 (0.61-1.18) 0.33
Ischemia driven TLR 3.43 (2.36-4.99) <0.00001 1.15 (0.57-2.34) 0.7
